Bicalutamide and Abemaciclib for AR-positive Triple-negative Breast Cancer
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Skin clinical trials.
This trial tests a combination of two oral drugs—bicalutamide and abemaciclib—for people with a specific type of advanced triple-negative breast cancer that grows in response to androgen hormones (AR-positive). The goal is to see if this treatment can shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman 18 years or older with triple-negative breast cancer that has come back or spread, and your latest cancer biopsy must show it is androgen receptor (AR)-positive (at least 1% of cells).
- You must have had at least one prior chemotherapy for advanced cancer, unless your doctor says it's not safe for you.
- You cannot have had prior treatment with abemaciclib or anti-androgen drugs like bicalutamide, abiraterone, or enzalutamide.
- If you have had a CDK4/6 inhibitor like palbociclib or ribociclib, it must be at least 6 months since your last dose.
- You must be able to swallow pills, have good organ function (kidney, liver, blood counts), and no serious heart or lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral “CDK” medicine in people with triple-negative breast cancer who are about to receive standard treatment. It’s designed to help researchers see whether the drug can control or improve the cancer early, using planned biopsies and scans.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.